Key facts
- It has raised $33.5M; the latest was Later Stage VC ($20.0M) in Sep 2024.
- Notable investors include Draper Associates, Illumina Ventures, DCVC Bio, Astellas Venture Management, Mansueto Office — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Syntax Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Syntax Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Syntax Bio
Operator of a cell therapy company, intended to generate the diversity of all cells in the body. The company's modified clustered regularly interspaced short palindromic repeats system automatically guides stem cells down lineages of choice through stepwise genetic instruction sets to mimic embryonic developmental processes, enabling the manufacturing of stem cells for therapies across many indications.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2018
- Employees
- 12
- Website
- syntax-bio.com/
- Ownership
- Privately Held (backing)
Syntax Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Syntax Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Syntax Bio in its N-PORT filings yet. We sweep new filings monthly.